On the Record · Bristol Myers Squibb
Bristol Myers Squibb competitors, on the record
The companies whose own annual reports name Bristol Myers Squibb as a competitor, each with the sentence it appears in and the filing it came from.
Who Bristol Myers Squibb names
Bristol Myers Squibb’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names Bristol Myers Squibb
Companies whose own annual reports name Bristol Myers Squibb as a competitor.
Word for word“Bristol Myers Squibb OPDIVO U.S., Europe, Asia Pacific & China” 10-K for 2025
Word for word“Bristol-Myers Squibb's anti-CD19 CAR-T therapy, Breyanzi ("liso-cel"), as well as anti-BCMA CAR-T therapy, Abecma ("ide-cel"), in collaboration with bluebird bio, are also marketed CAR-T products.” 20-F for 2025
Word for word“There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025
Word for word“Bristol-Myers Squibb's, or BMS's nivolumab and Merck's pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma's pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas.” 10-K for 2022
Read from Bristol Myers Squibb’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.